Skip to main content

Table 3 Ongoing clinical trials of new drug groups in AIHA

From: Autoimmune hemolytic anemia: current knowledge and perspectives

Intervention/ treatment Group of agents Condition or disease Phase of study
Sirolimus plus ATRA mTOR inhibitor plus tretinoin refractory AIHA 2 and 3 NCT04324411
Idelalisib vs. ibrutinib PI3Kδ inhibitor vs. BTK inhibitor autoimmune cytopenia in the course of CLL retrospective NCT03469895
Parsaclisib PI3Kδ inhibitor AIHA 2 NCT03538041
Ibrutinib BTK inhibitor steroid refractory warm AIHA 2 NCT03827603
refractory/relapsed AIHA 2 NCT04398459
Ibrutinib or idelalisib BTK inhibitor AIHA associated with CLL retrospective NCT03469895
Interleukine-2 cytokine resistant, warm AIHA 1 and 2 NCT02389231
Low dose rituximab plus alemtuzumab anti CD20 antibody plus anti CD52 antibody refractory autoimmune cytopenias 2 and 3 NCT00749112
Fostamatinib SYK inhibitor warm AIHA 3 NCT03764618
2 NCT02612558
SYNT001 (ALXN1830) anti-FcRn antibody warm AIHA 1 and 2 NCT03075878
SYNT001 (ALXN1830) vs. placebo 2 NCT04256148
M281 2 and 3 NCT04119050
RVT-1401 2 NCT04253236
Levamisole plus prednisolone immunomodulatory drug plus GKS warm AIHA 2 NCT01579110
BIVV009 (Sutimlimab) complement C1 inhibitor CAD 3 NCT03347422
3 NCT03347396
APL2 complement C3 inhibitor warm AIHA, CAD 2 NCT03226678
  1. AIHA autoimmune hemolytic anemia, ATRA all trans-retinoic acid, BTK Bruton’s tyrosine kinase, CLL chronic lymphocytic leukemia, FcRn neonatal crystallizable fragment of the receptor, mTOR mammalian target of rapamycin kinase, PI3K phosphatidylinositol 3-kinase, SYK spleen tyrosine kinase